Physician profile
Barbara E Wotherspoon
NPI 1619919198
$5,070.41
in general payments reported to CMS, 2019-2025
24 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $435 · 2021: $650 · 2022: $87.40 · 2023: $1,530 · 2024: $817 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Travel and Lodging: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.56 |
| Travel and Lodging | $1,159.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,730.84 | 2021-2023 | Altis |
| Intuitive Surgical, INC. | $990.28 | 2019-2020 | |
| Biotronik Nro, INC. | $479.83 | 2024-2025 | Prospera |
| Boston Scientific Corporation | $383.91 | 2019-2025 | Infinion 16 |
| Medtronic, INC. | $381.50 | 2021-2024 | Ligasure, Intellis Adaptivestim |
| Abbott Laboratories | $277.38 | 2021-2025 | Proclaim |
| Nevro Corp. | $195.75 | 2019 | |
| Indivior INC. | $106.77 | 2020 | |
| Medtronic USA, INC. | $72.00 | 2020 | |
| Abbvie INC. | $49.01 | 2022-2023 | Lo Loestrin Fe, Orilissa |
| Pfizer INC. | $46.76 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $43.18 | 2019-2021 | |
| Hologic Sales and Service, LLC | $38.18 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $37.32 | 2025 | Veozah |
| Organon LLC | $35.64 | 2021-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $30.29 | 2024 | |
| Mayne Pharma Commercial LLC | $30.28 | 2025 | |
| Davol INC. | $28.25 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $23.79 | 2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $22.24 | 2023 | Austedo Xr |
| Exeltis, USA INC. | $18.95 | 2025 | Slynd |
| Sumitomo Pharma America, INC. | $17.84 | 2024 | Myfembree |
| Therapeuticsmd, INC. | $16.25 | 2022 | |
| Exact Sciences Corporation | $14.17 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Wotherspoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.